palbociclib

{
  "id": "MLC-T-ONC-006262",
  "term": "palbociclib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat women and men with certain types of hormone-receptor positive, HER2-negative breast cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Palbociclib blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called Ibrance.",
    "An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression."
  ],
  "synonyms": [
    "Ibrance",
    "6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/palbociclib/"
}